Tivic Health Systems, Inc. (TIVC)
NASDAQ: TIVC · Real-Time Price · USD
0.846
-0.005 (-0.54%)
At close: Mar 9, 2026, 4:00 PM EDT
0.802
-0.044 (-5.17%)
After-hours: Mar 9, 2026, 7:03 PM EDT
Tivic Health Systems Employees
Tivic Health Systems had 7 employees as of December 31, 2024. The number of employees decreased by 2 or -22.22% compared to the previous year.
Employees
7
Change (1Y)
-2
Growth (1Y)
-22.22%
Revenue / Employee
$68,857
Profits / Employee
-$1,079,000
Market Cap
2.14M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | -2 | -22.22% |
| Dec 31, 2023 | 9 | -7 | -43.75% |
| Dec 31, 2022 | 16 | 9 | 128.57% |
| Dec 31, 2021 | 7 | -1 | -12.50% |
| Dec 31, 2020 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| WORK Medical Technology Group LTD | 238 |
| Biomerica | 54 |
| Nuwellis | 38 |
| ENvue Medical | 31 |
| Catheter Precision | 22 |
| Autonomix Medical | 11 |
| iTonic Holdings | 10 |
| Aethlon Medical | 9 |
TIVC News
- 5 days ago - Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma - Accesswire
- 19 days ago - Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10 - Accesswire
- 5 weeks ago - Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting - Accesswire
- 6 weeks ago - Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference - Accesswire
- 6 weeks ago - Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference - Accesswire
- 2 months ago - Tivic Health Systems, Inc. (TIVC) Discusses Acquisition of Biomanufacturing Assets and Strategic Transformation Transcript - Seeking Alpha
- 2 months ago - Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity - Accesswire
- 2 months ago - Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines - Accesswire